MULTIPLE MYELOMA

This study tested a new drug, belantamab mafodotin, in 221 adults with multiple myeloma that had not responded to at least three prior treatments. The drug is an antibody-drug conjugate that delivers a toxin directly to cancer cells. The goal was to see if it could shrink tumors …

This study tested a new way to do a stem cell transplant for people with high-risk multiple myeloma, a hard-to-treat blood cancer. Nineteen patients received a special type of cord blood transplant using a molecule called UM171 to grow more stem cells. The goal was to see if this…

This study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that stopped responding to standard treatments. The drug works by helping the body's immune system attack the cancer cells. The goal was to see if it is safe and can shrink or control the can…

This study tested a combination of three drugs (carfilzomib, lenalidomide, and dexamethasone) in 55 people with smoldering multiple myeloma, a condition that often turns into active multiple myeloma. The goal was to see if early treatment could stop or delay the disease. Particip…

This study tested a new form of the drug melphalan (EVOMELA) combined with other treatments before a stem cell transplant from a half-matched donor. It included 43 adults with blood cancers like multiple myeloma. The goal was to see if the treatment was safe and helped patients l…

This study tested a drug called palifermin in 34 adults with blood cancers who received stem cells from an unrelated donor. The goal was to see if palifermin could reduce severe graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body. P…

This early-phase study tested a new treatment called C-CAR088 in 9 people with multiple myeloma that had come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. The main goal was to check sa…

This early-stage study tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received the drug alone, and researche…

This study tested a combination of three drugs (pomalidomide, cyclophosphamide, and dexamethasone) in 100 adults with multiple myeloma whose cancer returned after initial treatment. Participants had previously received standard first-line therapy. The goal was to see how well the…

This study looked at 514 people with newly diagnosed multiple myeloma who were eligible for a stem cell transplant. Researchers wanted to see if giving the drug isatuximab as a shot under the skin worked as well as giving it through a vein. Both groups also received standard chem…

This study tested a combination of two drugs, pomalidomide and dexamethasone, in 84 people with advanced multiple myeloma whose cancer had stopped responding to two other standard treatments. The goal was to see if this new combination could shrink tumors or slow the disease. Par…

This study tested a two-step treatment for multiple myeloma, a blood cancer. Patients received high-dose chemotherapy with a stem cell transplant, then a second round with an added drug. The goal was to see if this approach could keep the cancer from coming back longer. 148 adult…

This study tested different doses and schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or not responded to at least three prior treatments. The goal was to see if changing the dose could reduce serious eye problems while still contr…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. The approach uses a drug called cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a serious side effect. The goal was to help more patient…

This early-phase study tested whether high doses of vitamin C, combined with a low dose of chemotherapy, is safe for people with multiple myeloma that has come back after several treatments. Six participants were enrolled to check for side effects and see if the combination helps…

This study tested a cancer drug called elranatamab in 86 people with multiple myeloma that returned or didn't respond to prior treatments. The drug was given as a shot under the skin, starting with low doses that gradually increased to reduce side effects. The goal was to see if …

This study tested a new three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) for people with multiple myeloma that had returned or stopped responding to three previous treatments. 112 adults took part, receiving either the new combo or two older drugs alone. The…

This study tested a combination of three drugs (lenalidomide, bortezomib, and dexamethasone) in 46 people newly diagnosed with multiple myeloma, a blood cancer. The goal was to see how well the treatment controlled the disease and what side effects occurred. While many patients r…

This early-stage trial tested a new treatment called CC-95266 in 130 adults with multiple myeloma that had come back or stopped responding to other therapies. The main goals were to check safety, find the right dose, and see if the treatment could shrink the cancer. While not a c…

This early-phase study tested the safety of adding TAK-079 to standard treatments for 50 adults newly diagnosed with multiple myeloma who were not eligible for stem cell transplant. The goal was to find the right dose and check for side effects. While the drug may help control th…

This study tested the drug nivolumab, alone or with other drugs, in 320 adults with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to check safety and side effects, especially when nivolumab was comb…

This study tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often leads to active cancer. The goal was to see which dose schedule best controlled the disease and reduced cancer cells. Participants had interm…

This study tested a combination of four drugs (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) in 46 people newly diagnosed with multiple myeloma, a blood cancer. The goal was to see how many patients achieved a very deep response, meaning no cancer cells could be found…

This study tested a combination of three drugs (carfilzomib, melphalan, and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma, a type of blood cancer. The goal was to find the safest dose of carfilzomib and see how well the combination w…

This study tested two different drug combinations to collect stem cells from 62 multiple myeloma patients before a stem cell transplant. The goal was to see which method worked better and had fewer side effects. The approach helps patients get enough healthy stem cells for transp…

This study tested a combination of daratumumab and dexamethasone in 64 adults with multiple myeloma that had stopped responding to three previous treatments. The goal was to see how many patients achieved a partial response or better. The treatment aims to control the disease, no…

This study tested whether adding the drug bortezomib to standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combination followed by a transplant f…

This study tested a combination of pomalidomide and dexamethasone in 63 patients with relapsed or refractory multiple myeloma who also have specific high-risk genetic changes (deletion 17p or translocation 4;14). The goal was to see how long the treatment could keep the disease f…

This early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, or colon cancer. The main goals were to check safety, find the best dose, and see if the drugs help control the disease. Participant…

This study tested a new treatment called bb2121 in people with multiple myeloma, a type of blood cancer. It included patients whose cancer had returned or was hard to treat, as well as those at high risk. The goal was to see how well bb2121 worked and how safe it was. About 312 p…

This early-phase study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to see if the combination is safe and effective. Participant…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the drugs worked together. Researchers measured side effects and tumor…

This study tested a combination of three drugs (pomalidomide, dexamethasone, and carfilzomib) in 25 people whose multiple myeloma had returned or stopped responding to prior treatments. The goal was to find the safest dose and see how well the drugs worked together to control the…

This study tested whether a drug called GPC-100, combined with propranolol and sometimes with G-CSF, can help collect enough stem cells for transplant in people with multiple myeloma. About 30 patients were split into two groups to compare the combinations. The goal was to see if…

This study tested a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and elotuzumab) in 15 people whose multiple myeloma had returned or stopped responding to treatment. The goal was to see if this mix could shrink tumors or eliminate signs of cancer. While so…

This study tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see how many patients achieved a very deep remi…

This study tested two ways to use the drug pomalidomide in people with multiple myeloma that has come back or stopped responding to treatment. All 23 participants first received a combination of clarithromycin, pomalidomide, and dexamethasone (ClaPD) for 4 cycles. Then, half rece…

This study tested a new treatment called anti-BCMA CAR T-cells (bb2121) in 40 adults with multiple myeloma who had a poor response after a stem cell transplant and maintenance therapy. The goal was to see if this one-time cell therapy could help achieve a complete remission. Whil…

This early-phase study tested a three-drug combination (ibrutinib, lenalidomide, and dexamethasone) in 14 people whose multiple myeloma had returned or stopped responding to treatment. The main goal was to find safe doses and identify side effects. While the approach aims to cont…

This study tested adding thalidomide to two other drugs (bortezomib and high-dose melphalan) before a stem cell transplant in 29 people with advanced multiple myeloma who had already failed a prior transplant. The goal was to find the safest dose of thalidomide and see if the com…

This pilot study tested whether a daily supplement of curcumin (from turmeric) and piperine (from black pepper) could slow or stop disease progression in 30 patients with early-stage prostate cancer, MGUS, or low-risk smoldering multiple myeloma. Participants took the supplement …

This study tested a drug called denosumab in 55 people with multiple myeloma and severe kidney problems. The goal was to see if it could help control bone damage caused by the cancer. Researchers measured changes in bone turnover markers and watched for side effects like low calc…

This early-phase study tested a new treatment called FT576, given alone or with another drug (daratumumab), in 31 people whose multiple myeloma had returned or stopped responding to prior therapies. The goal was to find the safest dose and see if the combination can help control …

This study offers continued treatment with elotuzumab and other drugs to multiple myeloma patients who were already benefiting from them in earlier studies but cannot get the drug commercially. 67 participants were enrolled to receive ongoing therapy while researchers tracked sid…

This study looked at whether a second stem cell transplant, using a personalized dose of busulfan plus bortezomib, could help control multiple myeloma that had come back after a first transplant. Thirty adults aged 18 to 75 took part. The goal was to see how many patients had the…

This study tested whether adding daratumumab to the standard two-drug therapy (pomalidomide and dexamethasone) helps people with relapsed or refractory multiple myeloma live longer without their cancer getting worse. The trial involved 304 adults who had already tried at least on…

This study tested whether adding vorinostat to the standard drugs lenalidomide and dexamethasone could help people with multiple myeloma whose cancer had stopped responding to lenalidomide. The trial included 25 participants and aimed to see if the combination could shrink tumors…

This study tested whether giving higher doses of carfilzomib together with lenalidomide and dexamethasone is safe and effective for people newly diagnosed with multiple myeloma. 29 participants took part to find the best tolerated dose and to measure how many cancer cells remain …

This study compared two different drug combinations for people newly diagnosed with multiple myeloma, a type of blood cancer. Over 1,500 patients aged 18-65 took part. The goal was to see which approach worked better at delaying the cancer's return, using a stem cell transplant a…

This early-phase study tested a new drug called JNJ-64407564 in 15 Japanese patients with multiple myeloma that had come back or stopped responding to other treatments. The drug is a special antibody that helps the immune system attack cancer cells. The main goal was to check saf…

This study tested a cancer drug called isatuximab given either as a shot under the skin or through an IV, along with two other medicines (pomalidomide and dexamethasone), in 56 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal…

This study tested a two-step treatment for multiple myeloma that returned after a donor stem cell transplant. Ten adults received lenalidomide and dexamethasone, followed by infusions of donor immune cells, to boost the body's ability to fight the cancer. The goal was to improve …

This study tested a new combination of drugs (daratumumab, lenalidomide, and dexamethasone) in 45 adults whose multiple myeloma had returned or stopped responding to treatment. The main goal was to check safety and find the right dose, while also measuring how well the drugs shra…

This study tested a combined bone marrow and kidney transplant from a partially matched family donor for 10 people with both a serious blood disorder and chronic kidney disease. The goal was to treat both conditions with one donor, potentially reducing the need for lifelong anti-…

This study tested a multi-step treatment plan for 40 people under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The approach included several rounds of different chemotherapy drugs, followed by a stem cell transplant using the patient's own cells, and …

This study tested whether adding daratumumab to the standard drugs lenalidomide and dexamethasone helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The trial included 737 adults who were not healthy enough for high-dose chemotherap…

This early-phase study tested an experimental drug called VS-6766, given by mouth on different schedules, in 104 adults with advanced solid tumors or multiple myeloma. The goal was to find a safe and tolerable dose, both when used alone and when combined with another drug (everol…

This phase 2 study tested a combination of three oral drugs (ixazomib, cyclophosphamide, and dexamethasone) as the first treatment for multiple myeloma in 12 newly diagnosed patients. The goal was to see if this all-oral regimen could control the disease effectively while causing…

This early-stage trial tested a new drug called cevostamab in 355 people with multiple myeloma that had returned or stopped responding to other treatments. The main goals were to check the drug's safety and find the right dose. Participants received the drug through an IV, and re…

This study tested whether adding an experimental drug (CT-011) and a cancer vaccine to standard stem cell transplant is safe and helps prevent multiple myeloma from returning. 35 adults with myeloma received the combination after transplant. The goal was to boost the immune syste…

This early-phase study tested whether giving patients their own specially grown natural killer (NK) cells, combined with the drug bortezomib, is safe for people with advanced solid tumors or leukemia that no longer respond to standard treatments. 35 adults received increasing dos…

This study tested whether fasting for a longer period each night could help overweight people with early signs of blood cancer (MGUS, smoldering multiple myeloma, or smoldering Waldenstrom macroglobulinemia) lose weight and possibly prevent the disease from progressing. Twenty-th…

This study tested a structured educational program called the Myeloma Pack for people with multiple myeloma. The goal was to see if learning more about their disease could reduce anxiety and depression and improve quality of life. 85 patients participated alongside their regular …

This study tested whether distance Reiki therapy can improve quality of life and immune function in 30 adults with multiple myeloma who had a stem cell transplant. Participants received either real distance Reiki, sham (fake) Reiki, or no extra treatment. The goal was to see if R…

This pilot study looked at whether providing plant-based, whole-food meals to multiple myeloma patients during stem cell transplant is practical and well-tolerated. The goal was to improve gut microbiome diversity, which is linked to better outcomes. 26 patients were enrolled to …

This study tested if wearing special cold caps on the head during high-dose chemotherapy and stem cell transplant could prevent hair loss in people with multiple myeloma. 31 participants used the Penguin cold caps to cool their scalp. The goal was to see if at least 75% of people…

This small pilot study tested a six-session exercise program called Health Through Activity in 5 adults with multiple myeloma who were on maintenance therapy and had trouble with daily activities due to their health. The goal was to see if the program was feasible and if it could…

This study looked at whether starting supportive care (like nutrition, psychology, and social help) right when someone is diagnosed with multiple myeloma improves their quality of life more than waiting 6 months. Twenty patients took part, and researchers measured their well-bein…

This study tested whether colesevelam, a drug used for high cholesterol, can safely improve diarrhea in people with multiple myeloma who take lenalidomide. 25 participants received colesevelam, and researchers measured if their diarrhea improved within 4 weeks. The goal was to fi…

This study tested a pain management program for 51 cancer survivors living in rural areas or who are Hispanic. The goal was to see if the program was easy to use and helpful for controlling cancer-related pain. Researchers measured how often participants used the program and how …

This study looked at how often people with chronic lymphocytic leukemia or multiple myeloma face money problems because of their treatment. About 218 patients and their doctors answered surveys about costs and available help. The goal was to measure how common financial difficult…

This study looked at nearly 1,900 male farmers over age 50 to see if pesticides are linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and asked about pesticide use. No treatment was given—the goal was simply to gather info…

This study looked at genetic information from over 1,300 stored samples of lymphoma, leukemia, and multiple myeloma to find new ways to classify these cancers. Researchers wanted to understand why some patients respond well to treatment while others do not. No new patients were r…

This study looked at whether certain blood test results (blood thickness, protein ratios, and red blood cell size variation) can help predict how well people with newly diagnosed multiple myeloma will do over the next year. Researchers followed 48 patients to see if these simple …

This study interviewed 9 people with multiple myeloma to learn about their experiences with different treatments and what factors are most important to them when making treatment decisions. The goal was to better understand patient preferences, not to test a new drug or cure. Res…

This study involved 20 adults newly diagnosed with multiple myeloma who were starting treatment with daratumumab. Researchers collected blood and urine samples before and 30 days after starting therapy to measure specific biomarkers that might signal early kidney injury. The goal…

This study looked at whether a substance in the blood called M-CSF can help doctors find bone damage caused by multiple myeloma. Researchers compared M-CSF levels in 111 people: some with multiple myeloma, some with a related condition called MGUS, and some healthy volunteers. Th…

This study looked at how well COVID-19 vaccines and boosters protect people with multiple myeloma, a blood cancer that weakens the immune system. Researchers enrolled 201 patients to track their vaccine history, booster uptake, and any side effects. The main goal was to see if it…

This study looked at 66 people with multiple myeloma to see how many also had autoimmune hemolytic anemia (AIHA), a condition where the body attacks its own red blood cells. Researchers measured how common AIHA is in these patients and whether it affects their prognosis and respo…

This study looked at whether newer imaging scans can better detect when early blood disorders (MGUS and smoldering myeloma) turn into active multiple myeloma. Thirty-one adults with these conditions received three types of scans to compare their results. The goal was to improve m…

This study looked at whether the COVID-19 vaccine triggers a strong immune response in people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose in 146 participants. The goal was to understand vaccin…

This study followed 482 people with multiple myeloma in China who were already taking or about to start the drug Ninlaro as part of their normal care. The goal was to collect information on side effects and how the drug is used in everyday practice, not to test a new treatment. N…